1,720,987 research outputs found
THU0639 AUTOMATED CAPTURE AND HIGH UPTAKE RATES OF PATIENT REPORTED OUTCOME MEASURES IN ROUTINE RHEUMATOLOGY PRACTICE
No full text10.1136/annrheumdis-2019-eular.3872Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 201
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
No full text10.1016/j.semarthrit.2019.01.001Seminars in Arthritis and Rheumatism49191-9
CALPROTECTIN EARLY RHEUMATOID ARTHRITIS ASSOCIATION WITH DISEASE ACTIVITY AND CLINICAL REMISSION
No full textEULAR781438-144
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
No full textACR (Americal College of Rheumatology) meetin
The Patient Acceptable Symptom State (PASS) in Asian rheumatoid arthritis (RA) patients
No full text10.1111/1756-185X.13545APLA
Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
No full text7
A vaccination update for rheumatologists—SARS-CoV-2, influenza and herpes zoster
No full text10.1111/1756-185X.14179INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES248979-98
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region
No full textBackground: Clinical remission is an attainable goal for Rheumatoid Arthritis (RA). However, data on RA remission rates from multinational studies in the Asia-Pacific region are limited. We conducted a cross-sectional multicentric study to evaluate the clinical remission status and the related factors in RA patients in the Asia-Pacific region. Methods: RA patients receiving standard care were enrolled consecutively from 17 sites in 11 countries from APLAR RA SIG group. Data were collected on-site by rheumatologists with a standardized case-report form. Remission was analyzed by different definitions including disease activity score using 28 joints (DAS28) based on ESR and CRP, clinical disease activity index (CDAI), simplified disease activity index (SDAI), Boolean remission definition, and clinical deep remission (CliDR). Logistic regression was used to determine related factors of remission. Findings: A total of 2010 RA patients was included in the study, the overall remission rates were 62•3% (DAS28-CRP), 35•5% (DAS28-ESR), 30•8% (CDAI), 26•5% (SDAI), 24•7% (Boolean), and 17•1% (CliDR), respectively, and varied from countries to countries in the Asia-Pacific region. Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) prescription rate was low (17•9%). Compared to patients in non-remission, patients in remission had higher rates of b/tsDMARDs usage and lower rates of GC usage. The favorable related factors were male sex, younger age, fewer comorbidities, fewer extra-articular manifestations (EAM), and use of b/tsDMARDs, while treatment with GC was negatively related to remission. Interpretation: Remission rates were low and varied in the Asia-Pacific region. Treatment with b/tsDMARDs and less GC usage were related to higher remission rate. There is an unmet need for RA remission in the Asia-Pacific region
D-penicillamine in Wilson's disease; recognizing the transition from benefit to harm
No full text10.1016/j.ensci.2021.100328eNeurologicalSci23100328
- …
